title: [Combination of cisplatin-mitomycin-vindesine for inoperable, non-small-cell bronchial cancers. French study group in pneumo-cancerology].
abstract: The efficacy of the association of cisplatinum-mitomycine and vindesine on inoperable non-small cell bronchial cancer has been assessed in a prospective study. Cisplatinum 120 mg/m2 and mitomycine 8 mg/m2 on day 1, day 28 and day 70, and vindesine 3 mg/m2 once per week for the first cycle, once every 15 days for the second and third cycles. 98 patients were included in the study between February 1989 and June 1990: there were 89 men and 9 women with a mean age of 60. There were 57 epidermoid cancers, 22 adenocarcinomas, 1 neuroendocrine carcinoma and 18 large cell cancers. There was an objective response (RO) in 25% (of whom 5% had a complete response) without any significant difference between the 56 cancers at stage III (32% RO) and 42 cancers in stage IV (17% RO). The median survival of the responders was 14 months again 5 months for the non-responders. The initial loss of weight seemed to be a prognostic factor because the number of objective responders was significantly greater in the patients with only a small weight loss: 37% of RO if the weight loss was less than 5%, against 11% for a weight loss of greater than 5%. The myelotoxicity of this association was important because 85% of those patients presented with a leucopenia at least grade II OMS. Peripheral neuropathies occurred in 27% of cases: 4 cases of cardiotoxicity were reported.
authors.affiliation: Département des Maladies Respiratoires, Hôpital Sainte-Marguerite, Marseille.
authors.forename: J P
authors.initials: JP
authors.lastname: Kleisbauer
authors.forename: P
authors.initials: P
authors.lastname: Thomas
authors.forename: M
authors.initials: M
authors.lastname: Perol
authors.forename: A
authors.initials: A
authors.lastname: Taytard
authors.forename: R
authors.initials: R
authors.lastname: Poirier
authors.forename: M J
authors.initials: MJ
authors.lastname: Collus
authors.forename: J C
authors.initials: JC
authors.lastname: Guerin
authors.forename: A
authors.initials: A
authors.lastname: Vergnenegre
authors.forename: P
authors.initials: P
authors.lastname: Balmes
authors.forename: P
authors.initials: P
authors.lastname: Carles
mesh_terms: D000206:Actuarial Analysis; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced / Q000453:epidemiology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008937:Mitomycins / Q000008:administration & dosage; D009367:Neoplasm Staging; D010166:Palliative Care / Q000379:methods*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000453:epidemiology; D011379:Prognosis; D011446:Prospective Studies; D012074:Remission Induction; D015996:Survival Rate; D014751:Vindesine / Q000008:administration & dosage; D015431:Weight Loss
chemical_list: D008937:Mitomycins; D002945:Cisplatin; D014751:Vindesine